- 现金
- 9378 元
- 精华
- 18
- 帖子
- 6849
- 注册时间
- 2002-12-5
- 最后登录
- 2003-9-5
|
5楼
发表于 2003-8-9 08:52
References
1. Blei AT. Hepatic encephalopathy. In: Bircher J, Benhamou JP, McIntyre N, et al, eds. Oxford textbook of hepatology. Oxford, UK: Oxford University Press, 1999:765-86.
2. Butterworth RF. The neurobiology of hepatic encephalopathy. Semin Liver Dis 1996;16:235-44.
3. Norenberg MD. Astrocytic-ammonia interactions in hepatic encephalopathy. Semin Liver Dis 1996;16:245-53.
4. Nomura F, Ohnishi K, Terabayashi H, et al. Effect of intrahepatic portal-systemic shunting on hepatic ammonia extraction in patients with cirrhosis. Hepatology 1994;20:1478-81.
5. Clemmesen JO, Larsen FS, Kondrup J, et al. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology 1999;29:648-53.
6. Lockwood AH, Yap EW, Wong WH. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 1991;11:337-41.
7. Kramer L, Tribl B, Gebdo A, et al. Partial pressure of ammonia versus ammonia in hepatic encephalopathy. Hepatology 2000;31:30-4.
8. Haussinger D, Kircheis G, Fischer R, et al. Hepatic encephalopathy in chronic liver disease: A clinical manifestation of astrocyte swelling and low grade cerebral edema? J Hepatol 2000;32:1035-8.
9. Mullen KD, Jones EA. Natural benzodiazepines and hepatic encephalopathy. Semin Liver Dis 1996;16:255-64.
10. Yurdaydin C, Walsh TJ, Engler HD, et al. Gut bacteria provide precursors of benzodiazepine receptor ligands in a rat model of hepatic encephalopathy. Brain Res 1995;679:42-8.
11. Zieve L, Doizaki WM, Zieve J. Synergism between mercaptans and ammonia or fatty acids in the production of coma: a possible role for mercaptans in the pathogenesis of hepatic coma. J Lab Clin Med 1974;83:16-28.
12. Rose C, Butterworth RF, Zayed J, et al. Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction. Gastroenterology 1999;117:640-4.
13. Jones EA, Basile AS. Does ammonia contribute to increased GABA-ergic neurotransmission in liver failure? Metab Brain Dis 1998;13:351-60.
14. Mullen KD, Ferenci P, Tartar R, et al. Clinical research in hepatic encephalopathy. Submitted for publication.
15. Gitlin N, Lewis DC, Hinkley L. The diagnosis and prevalence of subclinical hepatic encephalopathy in apparently healthy, ambulant, non-shunted patients with cirrhosis. J Hepatol 1986;3:75-82.
16. Weissenborn K, Ennen JC, Schomerus H, et al. Neuropsychological characterization of hepatic encephalopathy. J Hepatol (in press).
17. Donovan JP, Schafer DF, Shaw BW Jr, Sorrell MF. Cerebral oedema and increased intracranial pressure in chronic liver disease. Lancet 1998;351:719-21.
18. Stahl J. Studies of blood ammonia in liver disease. Ann Intern Med 1963;58:1-23.
19. Van der Rijt CCD, Schalm SW, De Groot GH, De Vlieger M. Objective measurements of hepatic encephalopathy by means of automated EEG analysis. Electroencephalogr Clin Neurophysiol 1984;57:423-6.
20. Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial. Am J Dig Dis 1978;23:398-406.
21. Teasdale G, Jennett B. Assessment and prognosis of coma after head injury. Acta Neurochir 1976;34:45-55.
22. Blei AT. Hepatic encephalopathy in the age of TIPS. Hepatology 1994;20:249-52.
23. Resnick RH, Ishihara A, Chalmers TC, Schimmel EM. A controlled trial of colon bypass in chronic hepatic encephalopathy. Gastroenterology 1968;54:1057-69.
24. Bustamante J, Rimola A, Ventura PJ, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999;30:890-5.
25. Merli M, Riggio O, Dally L, PINC (Policentrica Italiana Nutrizione Cirrosi). Does malnutrition affect survival in cirrhosis? Hepatology 1996;23:1041-6.
26. Plauth M, Merli M, Kondrup J, et al. ESPEN guidelines for nutrition in liver disease and transplantation. Clin Nutr 1997;16:43-55.
27. Bianchi GP, Marchesini G, Fabbri A, et al. Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross-over comparison. J Intern Med 1993;233:385-92.
28. Riggio O, Merli M, Capocaccia L, et al. Zinc supplementation reduces blood ammonia and increases liver ornithine transcarbamylase activity in experimental cirrhosis. Hepatology 1992;16:785-9.
29. Riggio O, Ariosto F, Merli M, et al. Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial. Dig Dis Sci 1991;36:1204-8.
30. Marchesini G, Fabbri A, Bianchi G, et al. Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology 1996;23:1084-92.
31. Van der Rijt CC, Schalm SW, Schat H, et al. Overt hepatic encephalopathy precipitated by zinc deficiency. Gastroenterology 1991;100:1114-8.
32. de Ledinghen V, Beau P, Mannant PR, et al. Early feeding or enteral nutrition in patients with cirrhosis after bleeding from esophageal varices? A randomized controlled study. Dig Dis Sci 1997;42:536-41.
33. Horst D, Grace NE, Conn HO, et al. Comparison of dietary protein with an oral, branched-chain enriched amino acid supplement in chronic portal-systemic encephalopathy. Hepatology 1984;2:279-87.
34. Van Thiel DH, Fagiuoli S, Wright HI, et al. Gastrointestinal transit in cirrhotic patients: Effect of hepatic encephalopathy and its treatment. Hepatology 1994;19:67-71.
35. Wolpert E, Phillips SF, Summerskill WH. Ammonia production in the human colon. Effects of cleansing, neomycin and acetohydroxamic acid. N Engl J Med 1970;283:159-64.
36. Rolachon A, Zarski JP, Lutz JM, et al. [Is the intestinal lavage with a solution of mannitol effective in the prevention of post-hemorrhagic hepatic encephalopathy in patients with liver cirrhosis? Results of a randomized prospective study]. Gastroenterol Clin Biol 1994;18:1057-62.
37. Cordoba J, Blei AT. Treatment of hepatic encephalopathy. Am J Gastroenterol 1997;92:1429-39.
38. Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med 1997;337:473-9.
39. Blanc P, Daures JP, Liautard J, et al. [Lactulose-neomycin combination versus placebo in the treatment of acute hepatic encephalopathy. Results of a randomized controlled trial]. Gastroenterol Clin Biol 1994;18:1063-8.
40. Clausen MR, Mortensen PB. Lactulose, disaccharides and colonic flora. Clinical consequences. Drugs 1997;53:930-42.
41. Warren SE, Mitas JA 2d, Swerdlin AH. Hypernatremia in hepatic failure. JAMA 1980;243:1257-60.
42. Uribe M, Campollo A, Vargas F, et al. Acidifying enemas (Lactitol and lactose) vs. non-acidifying enemas (tap water) to treat acute portal-systemic encephalopathy: A double-blind randomized clinical trial. Hepatology 1987;7:639-43.
43. Hawkins RA, Jessy J, Mans AM, et al. Neomycin reduces the intestinal production of ammonia from glutamine. Adv Exp Med Biol 1994;368:125-34.
44. Morgan MH, Read AE, Speller DC. Treatment of hepatic encephalopathy with metronidazole. Gut 1982;23:1-7.
45. Gubbins GP, Moritz TE, Marsano LS, et al. Helicobacter pylori is a risk factor for hepatic encephalopathy in acute alcoholic hepatitis: The ammonia hypothesis revisited. The Veterans Administration Cooperative Study Group No. 275. Am J Gastroenterol 1993;88:1906-10.
46. Vasconez C, Elizalde JI, Llach J, et al. Helicobacter pylori, hyperammonemia and subclinical portosystemic encephalopathy: Effects of eradication. J Hepatol 1999;30:260-4.
47. Loft S, Sonne J, Dossing M, Andreasen PB. Metronidazole pharmacokinetics in patients with hepatic encephalopathy. Scand J Gastroenterol 1987;22:117-23.
48. Kircheis G, Nilius R, Held C, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: Results of a placebo-controlled, double-blind study. Hepatology 1997;25:1351-60.
49. Stauch S, Kircheis G, Adler G, et al. Oral L-ornithine-L-aspartate therapy of chronic hepaticencephalopathy. Results of a placebo-controlled double-blind study. J Hepatol 1998;28:856-64.
50. Schafer DF, Jones EA. Hepatic encephalopathy and the gamma-amino-butyric acid system. Lancet 1982;1:18-20.
51. Basile AS, Hughes RD, Harrison PM, et al. Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure. N Engl J Med 1991;325:473-8.
52. Barbaro G, Di Lorenzo G, Soldini M, et al. Flumazenil for hepatic encephalopathy grade III and Iva in patients with cirrhosis: An Italian multicenter double-blind, placebo-controlled, cross-over study. Hepatology 1998;28:374-8.
53. James JH, Ziparo V, Jeppsson B, Fischer JE. Hyperammonaemia, plasma aminoacid imbalance, and blood-brain aminoacid transport: A unified theory of portal-systemic encephalopathy. Lancet 1979;2:772-5.
54. Morgan MY. Branched chain amino acids in the management of chronic liver disease. Facts and fantasies. J Hepatol 1990;11:133-41.
55. Fabbri A, Magrini N, Bianchi G, et al. Overview of randomized clinical trials of oral branched-chain amino acid treatment in chronic hepatic encephalopathy. JPEN J Parenter Enteral Nutr 1996;20:159-64.
56. Pomier-Layrargues G, Rose C, Spahr L, et al. Role of manganese in the pathogenesis of portal-systemic encephalopathy. Metab Brain Dis 1998;13:311-7.
57. Uribe M, Farca A, Marquez MA, et al. Treatment of chronic portal systemic encephalopathy with bromocriptine: A double-blind controlled trial. Gastroenterology 1979;76:1347-51.
58. Takashi M, Igarashi M, Hino S, et al. Portal hemodynamics in chronic portal-systemic encephalopathy. Angiographic study in seven cases. J Hepatol 1985;1:467-76.
59. Sakurabayashi S, Sezai S, Yamamoto Y, et al. Embolization of portal-systemic shunts in cirrhotic patients with chronic recurrent hepatic encephalopathy. Cardiovasc Intervent Radiol 1997;20:120-4.
60. McCrea M, Cordoba J, Vessey G, et al. Neuropsychological characterization and detection of subclinical hepatic encephalopathy. Arch Neurol 1996;53:758-63.
61. Groeneweg M, Quero JC, De Bruijn I, et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 1998;28:45-9.
62. Cordoba J, Cabrera J, Lataif L, et al. High prevalence of sleep disturbance in cirrhosis. Hepatology 1998;27:339-45.
63. Simmons F, Goldstein H, Boyle JD. A controlled clinical trial of lactulose in hepatic encephalopathy. Gastroenterology 1970;59:827-32.
64. Morgan MY, Hawley KE. Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: A double-blind, randomized trial. Hepatology 1987;7:1278-84.
65. Heredia D, Caballeria J, Arroyo V, et al. Lactitol versus lactulose in the treatment of acute portal systemic encephalopathy (PSE). A controlled trial. J Hepatol 1987;4:293-8.
66. Uribe M, Berthier JM, Lewis H, et al. Lactose enemas plus placebo tablets vs. neomycin tablets plus starch enemas in acute portal systemic encephalopathy. A double-blind randomized controlled study. Gastroenterology 1981;81:101-6.
67. Strauss E, Tramote R, Silva EP, et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 1992;39:542-5.
68. Sushma S, Dasarathy S, Tandon RK, et al. Sodium benzoate in the treatment of acute hepatic encephalopathy: A double-blind randomized trial. Hepatology 1992;16:138-44.
69. Pomier-Layrargues G, Giguere JF, Lavoie J, et al. Flumazenil in cirrhotic patients in hepatic coma: A randomized double-blind placebo-controlled crossover trial. Hepatology 1994;19:32-7.
70. Cadranel JF, el Younsi M, Pidoux B, et al. Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: A double-blind pragmatic randomized, placebo study. Eur J Gastroenterol Hepatol 1995;7:325-9.
71. Gyr K, Meier R, Haussler J, et al. Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: A double blind, randomised, placebo controlled multicentre study. Gut 1996;39:319-24.
72. Elkington SG, Floch MH, Conn HO. Lactulose in the treatment of chronic portal-systemic encephalopathy. A double-blind clinical trial. N Engl J Med 1969;281:408-12.
73. Germain L, Frexinos J, Louis A, Ribet A. [Double blind study of lactulose in 8 patients with chronic hepatic encephalopathy after portocaval shunt]. Arch Fr Mal App Dig 1973;62:293-302.
74. Blanc P, Daures JP, Rouillon JM, et al. Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: Results of a meta-analysis. Hepatology 1992;15:222-8.
75. Camma C, Fiorello F, Tine F, et al. Lactitol in treatment of chronic hepatic encephalopathy. A meta-analysis. Dig Dis Sci 1993;38:916-22.
76. Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977;72:573-83.
77. Orlandi F, Freddara U, Candelaresi MT, et al. Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: A randomized clinical study. Dig Dis Sci 1981;26:498-506.
78. Bresci G, Parisi G, Banti S. Management of hepatic encephalopathy with oral zinc supplementation: A long-term treatment. Eur J Med 1993;2:414-6.
79. Reding P, Duchateau J, Bataille C. Oral zinc supplementation improves hepatic encephalopathy. Results of a randomised controlled trial. Lancet 1984;2(8401):493-5.
80. Morgan MY, Jakobovits AW, James IM, Sherlock S. Successful use of bromocriptine in the treatment of chronic hepatic encephalopathy. Gastroenterology 1980;78:663-70.
81. Orlandi F, et al. Clinical trials of nonabsorbable disaccharide therapy in hepatic encephalopathy. In: Conn HO, Bircher J, eds. Hepatic encephalopathy: Syndromes and therapies. Bloomington, IL: Medi-Ed Press, 1994:209-17.
|
|